Search for dissertations about: "ibrutinib"
Showing result 6 - 10 of 15 swedish dissertations containing the word ibrutinib.
-
6. The role of estrogens and the microenvironment in lymphoma progression and drug sensitivity
Abstract : Lymphomas are a group of cancers which originate from lymphatic cells. More than 90% of the lymphomas belong to the group of Non-Hodgkin lymphoma (NHL), which in itself is a non-homogeneous group consisting of different NHL subtypes. Traditionally, lymphomas are not thought of as hormone-related cancers. READ MORE
-
7. ROR1 – a druggable target : preclinical studies of ROR1 and combinatorial partners in malignancies
Abstract : Cancer cells are masters of adaption, and their ability to sustain proliferative signaling presents a complicated challenge to cancer treatment. Therefore, novel drugs that attack key drivers of cancer cell growth are urgently needed. READ MORE
-
8. Effects of mutations in lymphoid malignancy and immunodeficiency disease
Abstract : Mutations are responsible for causing various human diseases, including several types of cancer and immunodeficiency syndromes. They can either be involved directly in the pathogenesis of the disease or by influencing the treatment efficacy and cause failure of the patient’s response to a specific therapy by adapting the targeted cell to resist the treatment. READ MORE
-
9. Gene regulation in normal and malignant B-lineage cells
Abstract : B-cells are the central players of humoral immunity. It is known that their development is orchestrated by a small group of transcription factors including the E-proteins and the FOXO proteins, yet this process is far from completely understood. READ MORE
-
10. Chronic lymphocytic leukemia : Studies from genetics to epidemiology with focus on the impact of different treatments
Abstract : The progress in our understanding of the biology and pathophysiology of chronic lymphocytic leukemia (CLL), as well as the development of new treatments, necessitates additional research on; (i) the impact of different therapies within subgroups of CLL patients, (ii) solid epidemiological data on the prevalence of CLL and on comorbidities within the CLL population, and (iii) new means of prognostication, as the value of traditional prognostic markers is uncertain when applied to new treatments.In paper I we studied the efficacy of chemo(immuno)therapy in stereotyped subsets #1 and #2. READ MORE